Tirzepatide 10mg
Dual GLP-1/GIP receptor agonist for weight management
In Stock (20 available)
SKU: ML-TIRZ-10MG
💰 Volume Discounts:
Buy 3+ vials = 10% off · Buy 5+ vials = 15% off
Description
Tirzepatide 10mg
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It has shown remarkable efficacy in clinical trials for weight management and glycemic control.
Key Benefits
- Dual receptor mechanism (GIP + GLP-1)
- Significant appetite reduction
- Improved insulin sensitivity
- Clinically proven weight loss results
- FDA-approved (as Mounjaro/Zepbound)
Research Highlights
- SURMOUNT clinical trials showed up to 22.5% body weight reduction
- Superior to semaglutide in head-to-head trials
Consult with a healthcare professional for personalized guidance.
Research References
Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity.
Meta-analysis examining how weight loss from therapies including tirzepatide drives histological improvement in metabolic liver disease.
Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.
Pilot study investigating testosterone supplementation in obese men with poor initial response to tirzepatide.
Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits.
Real-world study documenting tirzepatide's glycemic and cardiometabolic benefits in Indian adults with type 2 diabetes.
Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide.
Study evaluating holistic health outcomes beyond weight loss in a digital program integrating tirzepatide.
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg.
Cost-effectiveness analysis comparing tirzepatide versus semaglutide for achieving treatment targets in type 2 diabetes.
Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity.
Multicenter Italian real-world study evaluating tirzepatide's effectiveness in clinical obesity management.
Related Products
Retatrutide (RT3-GLP) 10mg
Triple agonist (GLP-1/GIP/Glucagon) for advanced weight management
Retatrutide (RT3-GLP) 20mg
Triple agonist (GLP-1/GIP/Glucagon) — higher dose for advanced protocols
MOTS-C 40mg
Mitochondrial peptide for metabolic optimization and longevity
Tirzepatide 20mg
Dual GLP-1/GIP receptor agonist — higher dose formulation